Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent
Authors:
Open Access
- 1 April 2016
- journal article
- research article
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. 8, 59-71
Abstract
Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent Katherine E Hanlon,1,2 Alysia N Lozano-Ondoua,1 Puja J Umaretiya,1 Ashley M Symons-Liguori,1 Anupama Chandramouli,1 Jamie K Moy,1 William K Kwass,1 Patrick W Mantyh,1 Mark A Nelson,3 Todd W Vanderah,1 1Department of Pharmacology, University of Arizona College of Medicine, Tucson, AZ, USA; 2Department of Biomedical Sciences, University of New England College of Osteopathic Medicine, Biddeford, ME, USA; 3Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, USA Introduction: Cannabinoid compounds, both nonspecific as well as agonists selective for either cannabinoid receptor 1 (CB1) or cannabinoid receptor 2 (CB2), have been shown to modulate the tumor microenvironment by inducing apoptosis in tumor cells in several model systems. The mechanism of this modulation remains only partially delineated, and activity induced via the CB1 and CB2 receptors may be distinct despite significant sequence homology and structural similarity of ligands. Methods: The CB2-selective agonist JWH-015 was used to investigate mechanisms downstream of CB2 activation in mouse and human breast cancer cell lines in vitro and in a murine mammary tumor model. Results: JWH-015 treatment significantly reduced primary tumor burden and metastasis of luciferase-tagged murine mammary carcinoma 4T1 cells in immunocompetent mice in vivo. Furthermore, JWH-015 reduced the viability of murine 4T1 and human MCF7 mammary carcinoma cells in vitro by inducing apoptosis. JWH-015-mediated reduction of breast cancer cell viability was not dependent on Gαi signaling in vitro or modified by classical pharmacological blockade of CB1, GPR55, TRPV1, or TRPA1 receptors. JWH-015 effects were calcium dependent and induced changes in MAPK/ERK signaling. Conclusion: The results of this work characterize the actions of a CB2-selective agonist on breast cancer cells in a syngeneic murine model representing how a clinical presentation of cancer progression and metastasis may be significantly modulated by a G-protein-coupled receptor.Keywords: cannabinoid receptor-2, CB2, breast cancer, JWH-015, MAPK/ERK, apoptosis, calciumKeywords
This publication has 55 references indexed in Scilit:
- Distinct Mechanisms of Calmodulin Binding and Regulation of Adenylyl Cyclases 1 and 8Biochemistry, 2012
- CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 SignalingJournal of Biological Chemistry, 2012
- Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasisBreast Cancer Research and Treatment, 2010
- Pharmacological characterization of GPR55, a putative cannabinoid receptorPharmacology & Therapeutics, 2010
- Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomasGlia, 2010
- Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve InjuryAnesthesiology, 2008
- The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurinProceedings of the National Academy of Sciences, 2006
- The Hallmarks of CancerCell, 2000
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990
- “Western Blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein AAnalytical Biochemistry, 1981